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Background: The neotropical, non-human primates (NHP) of the genus Saimiri and Aotus are recommended by the
World Health Organization as experimental models for the study of human malaria because these animals can be infected
with the same Plasmodium that cause malaria in humans. However, one limitation is the lack of immunological
tools to assess the immune response in these models. The present study focuses on the development and comparative
use of molecular and immunological methods to evaluate the cellular immune response in Saimiri sciureus.
Methods: Blood samples were obtained from nineteen uninfected Saimiri. Peripheral blood mononuclear cells (PBMC)
from these animals and splenocytes from one splenectomized animal were cultured for 6, 12, 18, 24, 48, 72 and 96 hrs in
the presence of phorbol-12-myristate-13-acetate and ionomycin. The cytokine levels in the supernatant were detected
using human and NHP cytometric bead array Th1/Th2 cytokine kits, the Bio-Plex Pro Human Cytokine Th1/Th2
Assay, enzyme-linked immunosorbent assay, enzyme-linked immunospot assays and intracellular cytokine secretion assays.
Cytokine gene expression was examined through TaqMan® Gene Expression Real-Time PCR using predesigned human
gene-specific primers and probes or primers and probes designed based on published S. sciureus cytokine sequences.
Results: The use of five assays based on monoclonal antibodies specific for human cytokines facilitated the detection of
IL-2, IL-4 and/or IFN-γ. TaqMan array plates facilitated the detection of 12 of the 28 cytokines assayed. However, only seven
cytokines (IL-1A, IL-2, IL-10, IL-12B, IL-17, IFN-β, and TNF) presented relative expression levels of at least 70% of the gene
expression observed in human PBMC. The use of primers and probes specific for S. sciureus cytokines facilitated
the detection of transcripts that showed relative expression below the threshold of 70%. The most efficient
evaluation of cytokine gene expression, in PBMC and splenocytes, was observed after 6–12 hrs of culture, except for LTA
in PBMC, whose expression was best analysed after 24 hrs of culture.
Conclusions: Real-time PCR facilitates the analysis of a large number of cytokines altered during malaria infection, and
this technique is considered the best tool for the evaluation of the cellular immune response in S. sciureus.
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Research involving non-human primates (NHP) has played
a critical role in many of the medical and scientific ad-
vances in the last decade. NHP are used because of the
similarities of these animals to humans in terms of
physiology, neuroanatomy, reproduction, development,
cognition, and social complexity. The close phylogen-
etic relationship of NHP to humans also makes these
animals excellent models for the study of a range of
biological phenomena. These similarities between humans
and NHP suggest that there is greater validity of the data
obtained from primate models compared to other animal
models, and experiments conducted using these models
might address questions that cannot be addressed using
other species.
For several infectious diseases, NHP are the only ani-
mal species susceptible to the infectious agent that
threatens human populations, and proof-of-concept of
candidate vaccines can therefore only be studied in these
species. The choice of the NHP model depends on the
nature of the pathogen. Hepatitis virus has a host range
restricted to humans and some NHP, including Calli-
thrix jaccus, Macaca mulatta, Macaca fascicularis and
chimpanzee, making these models valuable for studies
on hepatitis [1-5]. In AIDS research, NHP are used to
investigate the mechanisms underlying immune system
regulation and disease pathogenesis and to optimize
immunization strategies and vaccine safety and immuno-
genicity [6-8]. Other infectious agents for which NHP
have been valuable for vaccine research include influ-
enza virus, Trypanosoma cruzi, Mycobacterium, flavivi-
rus, poliovirus, Bacillus anthracis, Helicobacter pylori,
Ebola virus, and Plasmodium species [9].
Experimental models have been used from the incep-
tion of malariology and have provided important insights
into the mechanisms underlying Plasmodium diseases
[10,11]. Many studies on malaria have used rodent or NHP
experimental models, which have been long-standing tools
for malaria immunology and pathogenesis studies [12].
There is, however, no animal model as reliable as the NHP
for studying the basic mechanisms of human diseases [13].
In addition, recent studies have reported the natural infec-
tion of NHP, such as bonobos and chimpanzees, with hu-
man Plasmodium or plasmodial ancestors [14-16].
The NHP of the genera Aotus and Saimiri are the ex-
perimental models recommended by the World Health
Organization for research in malaria [17-20] because
these NHP develop a reproducible parasitaemia when in-
oculated with the blood stages or even sporozoites of the
human plasmodial species Plasmodium falciparum and
Plasmodium vivax, making these animals particularly
useful in preclinical trials of potential malaria vaccines
and for studies on pathogenesis [21-25]. In addition,
strains adapted to NHP have been used in studies to testschizonticidal anti-malarial drugs, malaria vaccine stud-
ies examining both pre-erythrocytic candidate antigens
and transmission-blocking vaccines and P. vivax biology
and genetic studies in both invertebrate mosquito vec-
tors and primate vertebrate hosts [26,27]. Preclinical
evaluation in these experimental models can provide valu-
able information on the immunogenicity, efficacy and safety
of a variety of formulations, facilitating a more refined se-
lection of the most appropriate formulations for evaluation
in humans.
Although the NHP model might offer many advan-
tages for the study of malaria, one important limitation
is the lack of specific reagents and immunological tools
for the reliable evaluation of primate immune re-
sponses. In some cases, immunological reagents for hu-
man molecules can be used, although sensitivity is
typically low [28,29]. Few cytokine studies have been
performed in Saimiri [30-32], although research efforts
have been focused on sequencing individual cytokine genes
of interest. Moreover, researchers have also attempted to
develop molecular tools to measure the mRNA expression
of IL-2, IL-5, IL-6, IL-10, IL-12, LTA, TNF, and IFN-γ
[30,33]. The present study focused on the development and
comparative use of molecular and immunological methods
to monitor the cellular immune response in Saimiri sciur-
eus monkeys, with the aim of providing information for fu-
ture immunization studies involving P. falciparum vaccine
candidates.
Methods
Animals and legal bioethics aspects
Nineteen clinically healthy NHP of the Saimiri sciureus
species from the breeding colony at the Department of
Primatology (CECAL)/Fiocruz in Rio de Janeiro, Brazil
were sampled and used in different assays. These ani-
mals were young, ranging between four and eight years
of age. The experiments involving Saimiri were reviewed
and approved through the Ethics Committee on Animal
Use of Fiocruz (CEUA, Fiocruz, Rio de Janeiro, Brazil
protocol P-391/07) and conducted in accordance with the
requirements of the laboratory biosafety rules (License n°
L-0062/08).
Tissue sampling, isolation and culture of cells
The animals were anaesthetized with a combination of
0.1 ml midazolan and 0.4 ml ketamine. Blood samples
were collected via femoral venipuncture, and cells were
obtained from 4 ml heparinized venous samples obtained
from each individual. The peripheral blood mononuclear
cells (PBMC) were separated through density gradient
centrifugation using Ficoll-Hypaque (Sigma), washed twice
in phosphate-buffered saline (PBS) (Sigma), resuspended
and cultured in RPMI medium containing 15 mM glutam-
ine (Gibco), 10 mM Hepes, 200 U/ml penicillin (Gibco),
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(Sigma) and 2 g/l sodium bicarbonate (Sigma) supple-
mented with 10% inactivated foetal calf serum (FCS) (Imu-
noquímica). The cells (2.5 × 105 cells/well) were activated
with a combination of 50–100 ng/ml phorbol 12-myristate
13-acetate (PMA-Sigma) and 250–500 ng/ml ionomycin
(Sigma) and cultured at 37°C in 5% CO2. The cells and
supernatant were collected after 6, 12, 18, 24, 48, 72 and
96 hrs. Subsequently, the cells were resuspended in RNA-
later solution (Ambion Life Technologies), incubated at
4°C overnight and subsequently stored at −20°C until
RNA extraction for the analysis of gene expression
using real-time PCR. The supernatant was stored at
−80°C prior to the detection and quantification of cy-
tokines. In all experiments, human blood samples from
two healthy donors from the Laboratory for Malaria
Research were collected and used as control.
One naive Saimiri monkey (PA51) was splenectomized,
and the splenocytes were used in cellular assays. A trained
veterinarian performed the splenectomy using keta-
mine (150 mg/kg) and xylazine (10 mg/kg) for anaes-
thesia in an aseptic surgical room. After spleen
removal and vascular resection, the wound was su-
tured, and the animal was allowed to recover under
the close supervision of trained staff. Immediately
after removal, a piece of the spleen was conditioned in
sterile RPMI 1640 medium supplemented with 10%
FCS and gently fragmented using a cell strainer. The
splenocytes were washed with RPMI 1640 medium
supplemented with 10% FCS, and 3 ml of erythrocyte
lysis buffer was added to the pellet and incubated for
5 min at 37°C. The splenocytes were cultured in vitro
under mitogenic stimulus with PMA (Sigma) and
ionomycin (Sigma) as previously described. The cells
were collected after 6, 12, 18, 24, 48, 72 and 96 hrs of
culture, resuspended in RNAlater solution (Ambion
Life Technologies), incubated at 4°C overnight and
subsequently stored at −20°C prior to RNA extraction
for the analysis of gene expression using real-time
PCR.
Cytometric bead array (CBA)
The cytokine levels were assessed using two BD Cyto-
metric Bead Array (CBA) Th1/Th2 Cytokine Kits (BD
Bioscience). One human kit for the detection of IL-2,
IL-4, IL-6, IL-10, TNF and IFN-γ and other NHP kit
(rhesus, cynomolgus, baboon, or pigtailed macaque
non-human primate species) for the simultaneous de-
tection of six cytokines (IL-2, IL-4, IL-5, IL-6, TNF
and IFN-γ) in the supernatant of PBMC cultures.
Samples from two Saimiri (V17 and V31) were used
for the evaluation of human CBA kit and samples
from three Saimiri (S8, S34 e S36) for the evaluation
of NHP CBA kit. Blood samples obtained from onehuman healthy donor were used as control. The cyto-
kine levels were determined in the test samples ac-
cording to the manufacturer’s instructions. Briefly,
25 μl of the supernatant obtained from PBMC cultures
was incubated for 2 hrs at room temperature (RT)
with 25 μl of cytokine capture beads and 25 μl of PE
detection reagent. After incubation, the samples were
washed once with washing buffer. The supernatants were
discarded, and the pellets were resuspended in 300 μl of
washing buffer for analysis on a FACS Calibur flow cyt-
ometer (Becton Dickinson). The concentration of each
cytokine in pg/ml was determined based on a standard
curve generated using the recombinant cytokines pro-
vided in the kit. In human CBA kit, the lower limits of
detection for IL-2, IL-4, IL-6, IL-10, TNF and IFN-γ
were 2.6, 2.6, 3.0, 2.8, 2.8 and 7.1 pg/ml, respectively,
while in NHP CBA kit, the lower limits of detection for
IL-2, IL-4, IL-5, IL-6, TNF and IFN-γ were 3.6, 0.9, 0.3,
0.1, 0.4, 3.3 pg/ml, respectively.Luminex - Th1/Th2 cytokine quantification in supernatant
cultures
The Bio-Plex Pro Human Cytokine Th1/Th2 Assay (Bio-
Rad Laboratories, Inc) containing fluorescent microspheres
conjugated to monoclonal antibodies specific to Th1- and
Th2-related cytokines, including IL-2, IL-4, IL-5, IL-10,
IL-12, IL-13, GM-CSF, IFN-γ, and TNF, was used.
The cytokine levels in the supernatants of PBMC cul-
tures were analysed according to the manufacturer’s in-
structions. Briefly, a 50 μl sample obtained from one
human and two Saimiri (V17 e V31) samples was di-
luted 1:4 with sample diluent, incubated with antibody-
coupled beads and washed. Subsequently, the samples
were incubated with biotinylated secondary antibodies,
followed by incubation with streptavidin-phycoerythrin.
The beads were read on a Luminex System (Bioplex 200,
Bio-Rad). The standard curves were generated with a dy-
namic range between 5 and 20,000 pg/ml, and the data
were analysed using Bioplex Manager Software.
A serial dilution of the standards was added to the plate
in duplicate to obtain a standard curve. Following the gen-
eration of a five-parameter logistic curve, the standard
recovery was calculated using the following equation:
(observed concentration/expected concentration) × 100. A
recovery range between 80 and 120% was used according
to the manufacturer’s recommendations. Any sample with
a standard recovery value in an area of the curve outside of
this range was not considered accurate, and samples were
considered positive if the values obtained were above the
limits of detection for IL-2, IL-4, Il-5, IL-10, IL-12, IL-13,
GM-CSF, IFN-γ and TNF that were 0.003, 0.001, 0.01,
0.006, 0.01, 0.009, 0.004, 0.008 and 0.03 pg/ml, respectively,
in accordance with the manufacturer’s recommendations.
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measurements
Several antibodies were used to determine the levels of
different cytokines in the culture supernatant, in accord-
ance with methodology previously described [34]. The
monoclonal antibodies used in the ELISPOT assays are
listed in Table 1.
Blood samples from eight Saimiri sciureus (U1, R1,
O13, O17, Q3, Q7, J3 and J7) and from one clinically
healthy human donor were used in ELISPOT assays.
MultiScreen-IP 96-well plates (Millipore) were coated
at 4°C overnight with 100 μl of cytokine monoclonal
antibody at a concentration of 8 μg/ml in filtered
carbonate-bicarbonate buffer (pH 9.6). The plates were
subsequently washed three times with sterile PBS, and
the uncoated sites were blocked with 200 μl of PBS con-
taining 10% FCS (Imunoquímica) for 2 hrs at 37°C in 5%
CO2. Approximately 2 × 10





IFN-γ capture mAb GZ-4 Mabtech
IFN-γ biotin mAb 7-B6- Mabtech
IFN-γ capture B27 BD Bioscience
IFN- γ biotin 4SB3 BD Bioscience
IL-4 capture 8D4-8 BD Bioscience
IL-4 biotin MP4-25D2 BD Bioscience
IL-4 capture mAb IL4-I Mabtech
IL-4 biotin mAb IL4-II Mabtech
IL-5 capture TRFK5 BD Bioscience
IL-5 biotin JES1-5A10 BD Bioscience
IL-5 capture mAb TRFK-5 Mabtech
IL-5 biotin mAb 5 A10 Mabtech
IL-10 capture JES3-9D7 BD Bioscience
IL-10 biotin JES3-12G8 BD Bioscience
IL-10 capture 2617KIa BD Bioscience
IL-10 biotin 2617KIb BD Bioscience
IL-10 capture mAb 9D7 Mabtech
IL-10 biotin mAb 12 G8 Mabtech
IL-10 capture 945A5D11 Biosource
IL-10 biotin 945A5A10 Biosource
IL-13 capture mAb IL13 I Mabtech
IL-13 biotin mAb IL13 Mabtech
TNFcapture mAb1 BD Bioscience
TNF biotin mAb11 BD Bioscience
TNFcapture 2637KIa BD Bioscience
TNF biotin 2637KIb BD Bioscienceto each precoated well and stimulated for 18 hrs with
50 ng/ml PMA (Sigma) and 250 ng/ml ionomycin (Sigma)
in complete RPMI 1640 medium containing 15 mM
glutamine (Sigma), 10 mM Hepes, 200 U/ml penicillin
(Sigma), 200 μg/ml streptomycin (Sigma), 3 mg/ml genta-
micin (Sigma) and 2 g/l sodium bicarbonate (Grupo
Química) and supplemented with 10% inactivated FCS
(Imunoquímica). After three washes with PBS and three
washes with PBS/0.05% Tween 20 (PBS/T20 washing buf-
fer), 100 μl of 1 μg/ml diluted biotinylated antibody was
added. The plates were incubated for 1 hr at RT and
subsequently washed three times with washing buffer.
Streptavidin conjugated to horseradish peroxidase (BD Bio-
science) was diluted 1:1000 in washing buffer, and 100 μl of
this dilution was added to each well. The plates were incu-
bated for 1 hr at RT, followed by washing three times with
washing buffer and three times with PBS. The plates were
developed using the AEC Substrate Kit (BD Bioscience)ted for reactivity with Saimiri cytokines in ELISA and
References Reactivity
Human Saimiri
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drops of AEC substrate. One-hundred μl of the substrate
was added to each well, and the plate was incubated until
red spots emerged (10–15 min). Colour development was
terminated using washing buffer. The plates were air-dried,
and the spot numbers were counted using an Immunospot
Series 3B Analyzer (Cellular Technology). The spot count
in unstimulated, negative control wells was subtracted from
that in the test wells. The mean number of spot-forming
units (SFU) in the paired wells was multiplied by four to
obtain the SFU per 106 PBMC. Counts ≥20 SFU/106 PBMC
and at least ≥ two-fold greater than the background counts
were considered positive responses.Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed using the same pairs of monoclo-
nal antibodies (Table 1) and blood samples obtained
from three Saimiri sciureus (B11, J7 and N5) and from
one human donor were used in ELISA assay. Briefly, 96-
well, flat-bottomed microtitre plates (Nunc) were coated
with 100 μl of anti-human monoclonal cytokine detec-
tion antibodies at 4 μ g/ml (diluted in 0.1 M NaHCO3).
After overnight incubation at 4°C, the plates were
washed three times with sterile PBS, and the uncoated
sites were blocked with 200 μl of PBS containing 10%
FCS for 2 hrs at 37°C. After subsequent washing, 100 μl
of the supernatant obtained from the culture samples
was added to duplicate wells, and the plates were incu-
bated for 2 hrs at 37°C. The plates were subsequently
washed, and 100 μl of biotinylated anti-human cytokine
detection antibody at 1 μg/ml (1/250 dilution) andTable 2 Commercially available human-specific antibodies tes
Reagents Clones Suppliers
IFN-γ capture mAb GZ-4 Mabtech
IFN-γ biotin mAb 7-B6-1 Mabtech
IFN-γ capture B27 BD Bioscience
IFN-γ biotin 4SB3 BD Bioscience
IL-4 capture 8D4-8 BD Bioscience
IL-4 biotin MP4-25D2 BD Bioscience
IL-5 capture TRFK5 BD Bioscience
IL-5 biotin JES1-5A10 BD Bioscience
IL-10 capture JES3-9D7 BD Bioscience
IL-10 biotin JES3-12G8 BD Bioscience
IL-10 capture 945A5D11 Biosource
IL-10 biotin 945A5A10 Biosource
IL-13 capture mAb IL13-I Mabtech
IL-13 biotin mAb IL13-II Mabtech
TNF capture mAb1 BD Bioscience
TNF biotin mAb11 BD Bioscience100 μl of streptavidin peroxidase at 2.5 μg/ml. (1/250 di-
lution) were added. After incubation for 1 hr at 37°C
and additional washing, 100 μl/well of orthophenyledia-
mine (OPD) in citrate-phosphate buffer (10 mg/25 ml
plus 10 ml H2O2) (pH 5.0) was added to each well and
incubated for 30 min at RT in the dark, followed by the
addition of 50 μl/well 2 N H2SO4 to terminate the reac-
tion. The absorbance was read at 405 nm using a spec-
trophotometer (Spectra Max 250; Molecular Devices). A
standard curve was constructed for each cytokine using
different dilutions of human recombinant cytokines.Intracellular cytokine secretion (ICS)
Immune cell activation was also determined according
to the percentage of cells producing cytokines after
in vitro stimulation. Blood samples from one Saimiri
(B11) and from one human donor were used for the
evaluation of ICS. Briefly, 1 × 106 purified PBMC/ml
were cultured in complete RPMI-1640 medium contain-
ing 15 mM glutamine (Sigma), 10 mM Hepes, 200 U/ml
penicillin (Sigma), 200 μg/ml streptomycin (Sigma),
3 mg/ml gentamicin (Sigma), and 2 g/l sodium bicarbonate
(Grupo Química) and supplemented with 10% inactivated
FCS (Imunoquímica) on 24-well plates and incubated for
24 hrs at 37°C, 5% CO2. Cells were either cultured in the
presence of 100 ng/ml PMA (Sigma) and 500 ng/ml iono-
mycin (Sigma) or in the absence of mitogen. To block cyto-
kine secretion, the protein transport inhibitor brefeldin A
(2.5 μg/ml – BD Bioscience) was added to all samples after
12 hrs of culture. After 24 hrs, the cells were harvested and
washed with PBS. Another incubation with 100 μl ofted for reactivity with Saimiri cytokines in ICS assays
References Human Saimiri
mAb GZ-4 + +















Table 3 Assays identifications for the genes used in
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bovine serum albumin (BSA) was performed at RT. After
centrifugation at 1,500 rpm for 10 min, the cells were sub-
sequently incubated for 30 min at RT with anti-human
monoclonal cytokine detection or capture antibodies
(Table 2) previously diluted in permeabilization solution.
After two washes with PBS/10% FCS/1% BSA, the cells
were incubated for 30 min with anti-mouse IgG FITC-
labeled in permeabilization solution. The cells were
washed twice with PBS/0.2% saponin and once with PBS
and then resuspended in 2% paraformaldehyde. The ex-
periments were analysed using a FACSCalibur flow cyt-
ometer (FACSCalibur, BD Biosciences). Over 100,000





























IFNG AIRR97VAnalysis of gene expression using TaqMan Array Human
Cytokine Assays for real-time PCR
The gene expression of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-8, IL9, IL-10, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18,
IFN-α, IFN-β, IFN-γ, LTA, TNF, the 18S control, and three
candidate endogenous control genes (GAPDH, HPRT1
and GUSB) was assessed through real-time PCR using
TaqMan® Gene Expression Array Plates (Applied Bio-
systems) containing predesigned, gene-specific primers
and probes (Table 3). Additional primers and probes
were designed based on the published Saimiri sciureus
sequences for IL-4, IL-5, IL-6, LTA and IFN-γ (IL-4:
GenBank DQ985388.1; IL-5: GenBank AF294756.1; IL-6:
GenBank AF294757.1 and LTA: GenBank FJ589021.1). The
gene expression of IL-4, IL-5, IL-6 and LTA was also
assessed through real-time PCR using Custom Taq-
Man® Gene Expression Assays (Table 3).
In order to evaluate the analysis of gene expression
of cytokines, it was used a total of nine Saimiri (V17,
V31, 24, 149, 51, S8, S34, S36 and PA51) and one hu-
man blood samples. RNA was extracted from triplicate
wells of PBMC and splenocytes using the PureLink
RNA Mini Kit (Ambion, Inc.) according to the manufac-
turer’s instructions. Reverse transcription was performed
using High Capacity cDNA Reverse Transcription (Applied
Biosystems). Briefly, 10 μl of each extracted RNA was
added to 10 μl of reaction mix containing 2 μl of 10x
RT buffer, 0.8 μl of 25X dNTP Mix, 2 μl of 10X RT
Random Primers, 1 μl of MultiScribe™ Reverse Tran-
scriptase and 4.2 μl of nuclease-free water. The thermal
cycling conditions consisted of 25°C for 10 min, 37°C
for 120 min and 85°C for 5 min.
Each well of the TaqMan® Array Plate was reconsti-
tuted using 10 μl of TaqMan® Gene Expression Master
Mix (Applied Biosystems) and 10 μl of template
cDNA. For custom assays, 9 μl of template cDNA was
added in a 20-μl reaction volume containing 1 μl of
the 20x TaqMan Gene Expression Assay Mix and 10 μlof the 2x TaqMan Gene Expression Master Mix. The
reaction was performed using an Applied Biosystems
real-time PCR 7500 System with the following cycling
Riccio et al. Malaria Journal  (2015) 14:166 Page 7 of 17conditions: 50°C for 2 min and 95°C for 10 min,
followed by 40 cycles of 95°C for 15 sec and 60°C for
60 sec. The calculation method used for relative quan-
tification was the comparative CT method. The rela-
tive expression was determined as the expression of
the corresponding genes in PBMC obtained from the
healthy human donor or of the corresponding genes in
unstimulated PBMC or splenocytes cultures.Results
In the present study, the gene expression of cytokines from
Saimiri was analysed in PBMC stimulated with PMA and
ionomycin. The cross-reactivity of human cytokine anti-
bodies for cytokines secreted by Saimiri cells was evaluated
using Luminex, CBA, ELISA, ELISPOT, and ICS. For all
employed assays, the mononuclear cells were stimulated
using mitogens, and human cells or the supernatants ob-
tained from human cells were used as controls.Figure 1 Dotplots of cytokine in the supernatants of PBMC using CBA kit.
obtained from (A) a healthy donor in the presence of PMA/ionomycin; (B)
V31 in the presence of mitogen. a1 (IL-2), a2 (IL-4), a3 (IL-6), a4 (IL-10), a5 (THuman and non-human BD cytometric bead array
Th1/Th2 cytokine kit
The CBA assays were used to analyse the secretion of cyto-
kines (IL-2, IL-4, IL-5, IL-6, IL-10, TNF, and IFN-γ) in
PBMC cultures from five Saimiri monkeys and one human
donor. As expected, upon in vitro stimulation of human
mononuclear cells with PMA/ionomycin, increased cyto-
kine secretion was observed in the supernatants of stimu-
lated cells compared to unstimulated cultures (Figure 1).
However, the use of both human and non-human CBA kits
facilitated the detection of only IL-2 in the supernatants of
cell cultures from Saimiri, even after 6 hrs of stimulation
with mitogens (Figure 1).Luminex
The ability of Bio-Plex Pro Human Cytokine Th1/Th2
Assay Kit to detect S. sciureus IL-2, IL-4, IL-5, IL-10, IL-12,
IL-13, GM-CSF, IFN-γ and TNF cytokines was tested usingSupernatant from PBMC cultured in presence or absence of stimulus
Saimiri V17 in the absence of stimulus; (C) Saimiri V17; and, (D) Saimiri
NF), and a6 (IFN-γ).
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monkeys and one healthy donor after stimulation with
PMA/ionomycin for 6, 12, 18, 24, 48, 72 and 96 hrs. As
expected, Luminex assay was able to detect all evalu-
ated cytokines in the supernatants from mitogenic
stimulated-human PBMC (Figures 2 and 3). The higher
responses for each cytokine were: 12 hrs for IL-2; 48
hrs for IL-4, IL-10, IL-12, IL-13 and IFN-γ; 72 hrs for
TNF and; 96 hrs for IL-5 and GM-CSF. In contrast,
only IL-2 was detected in the supernatant of PBMC
cultures isolated from Saimiri V31 and V17, showing
higher levels after 48 hrs and 96 hrs, respectively
(Figure 3).Figure 2 Cytokine concentrations in the supernatant of PBMC using the Lu
healthy human donor and cultured in the presence or absence of mitogenELISA and ELISPOT assays
The cross-reactivity of anti-human cytokines antibodies
with cytokine produced by Saimiri stimulated PBMC was
also evaluated by ELISA and ELISPOT.
ELISA and ELISPOT assays for the detection of
TNF, IFN-γ, IL-4, IL-5, IL-10, and IL-13 were per-
formed using fresh PBMC isolated from ten Saimiri
monkeys and one healthy human donor. Table 1 shows
the information for the human-specific antibodies
used to test for reactivity in S. sciureus cells. In both
ELISPOT and ELISA assays, only anti-human anti-
bodies from Mabtech suppliers facilitated the meas-




Figure 3 Detection of IL-2 in the supernatant of PBMC from Saimiri sciureus using Luminex assay. IL-2 concentration in the supernatant of
cells cultured in the presence or absence of mitogenic stimulus from (A) a healthy human donor and (B and C) two Saimiri sciureus (V17
and V31) samples.
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PBMC cultures and the supernatant obtained from cul-
tured S. sciureus cells (Table 1). The results containing
the numbers of SFU in ELISPOT assays and the optical
densities (O.D.) values obtained in ELISA for IFN-γ
and IL-4 are represented in Figure 4.ICS assay
The ICS assay was performed using human monoclonal
antibodies for IL-4, IL-5, IL-10, IL-13, IFN-γ, and TNF and
the positivity was determinate setting the region of
cytokine-producing lymphocytes using mitogen stimulated
and non-stimulated human PBMC cultures. However, only
Figure 4 Results of the IFN-γ and IL-4 responses to PMA/ionomycin activation of PBMC from Saimiri sciureus samples. Samples from nine Saimiri
(U1, R1, O13, O17 Q3, J3, J7 B11 and N5) and one clinically healthy human donor (HUM) were cultured in absence or presence of PMA/ionomycin
(PMA/Ion) for 18 hrs. The results of ELISPOT for (A) IFN-γ and (B) IL-4 are presented as the mean of the number of SFU/106 cells ± SD. Mean of
OD values obtained ELISA assays for (C) IFN-γ and (D) IL-4 ± SD.
Figure 5 Relative expression of cytokines in PBMC from Saimiri sciureus
using TaqMan® Gene Expression Array Plates. Gene expression analysis of
IFN-γ, IL-10, IL-12B, IL-17A, IL-1A, IL-2 and TNF in PBMC from two Saimiri
sciureus (V17 and V31) cultured in the presence of PMA/ionomycin for 12
hours. The relative expression was determined as the expression of the
corresponding genes in PBMC obtained from the healthy human donor.
Riccio et al. Malaria Journal  (2015) 14:166 Page 10 of 17the anti-IFN-γ (clones mAb GZ-4 and 7-B6-1) human anti-
bodies from Mabtech supplier facilitated the detection of
this cytokine in both human and NHP cells (Table 2).
Gene expression using real-time PCR
In the first experiment, PBMC from two Saimiri (V17
and V31) samples and one human sample were cultured
in the presence or absence of PMA/ionomycin for 6, 12,
24, 48 and 72 hrs. Gene expression analysis was per-
formed using TaqMan® Gene Expression Array Plates. A
total of 12 of the 28 cytokines assayed were detected in
NHP samples, including IL-1A, IL-2, IL-4, IL-5, IL-6, IL-
10, IL-12B, IL-17, IFN-β, IFN-γ, LTA, TNF, and two
housekeeping genes. However, only seven cytokines (IL-
1A, IL-2, IL-10, IL-12B, IL-17, IFN-β, and TNF) pre-
sented relative expression of at least 70% of the corre-
sponding genes in PBMC culture obtained from the
healthy human donor (Figure 5). As expected, the gene
expression of the 28 cytokines and four housekeeping
genes in PBMC from the human donor was readily
detected.
In the second experiment, PBMC from three Saimiri
(24, 149 and 51) samples and PBMC obtained from one
human blood sample were cultured in the presence or
absence of PMA/ionomycin for 12, 24 and 48 hrs. Gene
expression analysis using primers and probes for IL-4,
IL-5, IL-6, LTA, and IFN-γ was performed using theCustom TaqMan Gene Expression Assay with primer
sets specifically designed based on Saimiri sequences.
The results revealed the gene expression levels of the
five cytokines in PBMC from Saimiri, whereas no gene
expression was detected in human PBMC (Figure 6).
In order to confirm the results obtained in the first
and second experiments, in the third experiment, PBMC
from three Saimiri (S8, S34 and S36) samples and from
Figure 6 Plots showing real-time PCR amplification using custom TaqMan® Gene Expression Assays. Samples from three Saimiri sciureus (24, P51
and 149) and one human health donor (HUM) were cultured in absence (BR) or presence of PMA/ionomycin (PMA ION) for 12 h. Delta Rn versus
cycle amplification plots were obtained using primers and probes for (A) IL-4, (B) IL-5, (C) IL-6, (D) LTA, and (E) IFN-γ. The lines represent the
threshold.
Riccio et al. Malaria Journal  (2015) 14:166 Page 11 of 17
Riccio et al. Malaria Journal  (2015) 14:166 Page 12 of 17one human donor sample were cultured in the presence
or absence of PMA/ionomycin for 12, 24 and 48 hrs.
Gene expression of IFN-γ, IL-10, IL-12B, IL-17A, IL-1A,
IL-2 and TNF was assessed using TaqMan Gene Expres-
sion Plates and the gene expression of IL-4, IL-5, IL-6,
LTA, and IFN-γ was assessed using Custom TaqMan
Gene Expression Assay. The TaqMan Gene Expression
Plates facilitated the detection of the gene expression of
IL-1A, IL-2, IL-10, IL-12B, IL-17, IFN-β, and TNF in
PBMC from Saimiri, showing a relative expression of at
least 70% of the gene expression observed in the PBMC
obtained from the human donor in the presence of
PMA/ionomycin (Figure 7). Similarly, the Custom Taq-
Man Gene Expression Assay revealed the gene expres-
sion of IL-4, IL-5, IL-6 LTA, and IFN-γ, although
expression of these genes was not detected in human
PBMC (Figure 8).
In the fourth experiment, PBMC and splenocytes ob-
tained from one Saimiri (PA51) sample were cultured in
the presence or absence of PMA/ionomycin for 3, 6, 12,
24, 48 and 72 hrs, and the gene expression was analysed
using TaqMan Gene Expression Plates and the Custom
TaqMan Gene Expression Assay. The relative expression
was determined as the expression of the corresponding
genes in unstimulated PBMC or splenocytes cultures.
Gene expression of IL-1A, IL-2, IL-10, IL-12B, IL-17,
IFN-β, and TNF was detected using the plates, and the
Custom TaqMan Gene Expression Assay revealed the
gene expression of IL-4, IL-5, IL-6 LTA, and IFN-γ in
both PBMC and splenocytes from Saimiri. Furthermore,
the results showed that the optimal time point for the
evaluation of gene expression for the studied cytokines
was at 6–12 hrs after culture, with the exception of LTAFigure 7 Relative expression of cytokines in PBMC from Saimiri sciureus
using TaqMan® Gene Expression Array Plates. The gene expression
analysis of IFN-γ, IL-10, IL-12B, IL-17A, IL-1A, IL-2 and TNF from three
Saimiri sciureus (S8, S34 and S36) cultured in the presence of PMA/
ionomycin for 12 hours. The relative expression was considered as
the expression of the corresponding genes in PBMC obtained from
the healthy human donor.in PBMC, which exhibited optimal expression after
24 hrs of culture (Figure 9).
Discussion
Malaria remains a serious public health problem and
the most important parasitic disease in developing
countries in tropical regions [35]. The development of
an effective vaccine represents an important measure
for disease control, as this treatment approach would
be preventative. For effective vaccine development, it is
essential to understand the mechanisms underlying the
acquisition of malaria immunity in humans [36-39].
However, studies in humans are complex and beyond
ethical limitations [40,41], and many other limitations,
such as the lack of access to relevant organ and tissue
samples and the difficulty to manipulate the immune
response, make the use of experimental models neces-
sary. Therefore, the use of experimental models phylo-
genetically related to humans is ideal. Indeed, the
WHO has recommended the use of neotropical pri-
mates of the genus Aotus and Saimiri for experimental
studies on malaria [17].
Notwithstanding these benefits, there are restric-
tions to the use of these animals, and the lack of spe-
cific reagents represents an important constraining factor.
Therefore, the development and use of immunological
and molecular tools could facilitate the reliable evaluation
of the immune response in preclinical trials of malaria vac-
cines and mediate the characterization of the pathogenesis
of disease in these animals [42-45].
Cytokines secreted from cells of the immune system
play essential roles during malaria [46]. Thus, specific
reagents and assays for the detection and quantifica-
tion of these molecules could provide information
concerning the immunological and physio-pathological
changes that occur during experimental infection of these
animals.
Other studies involving Saimiri and Aotus have previ-
ously been conducted for the development of molecular
reagents. Several genes encoding molecules involved in
the immune response, such as cytokines, Duffy blood
factor, T cell immunoglobulin receptor, and Toll-like re-
ceptors, have been sequenced, and these results have
shown greater than 80% identity to the human counter-
parts. For instance, degrees of identity between 91.4 and
98.1% for the sequences of IL-1β, IL-2, IL-5, IL-6, IL-10,
IFN-γ, and TNF from S. sciureus and other NHP and
humans were observed [30]. These data suggest that hu-
man sequences as templates for the design of Saimiri-
specific primers and probes may be used to obtain amp-
lification products to study cellular immune responses in
Saimiri and Aotus [33,47,48].
In the present study, molecular and immunological tools
were developed to evaluate the immune response of the
Figure 8 Plots showing real-time PCR amplification using custom TaqMan® Gene Expression Assays. Samples from three Saimiri sciureus (S8, S36
and S34) and one healthy human donor (HUM) were cultured in absence (BR) or presence of PMA/ionomycin (PMA ION) for 12 h, 24 and 48 h.
Delta Rn versus cycle amplification plots were obtained using primers and probes for (A) IL-4, (B) IL-5, (C) IL-6, (D) LTA, and (E) IFN-γ. The lines
represent the threshold.
Riccio et al. Malaria Journal  (2015) 14:166 Page 13 of 17
Figure 9 Kinetics of cytokine gene expression in PBMC and splenocytes. The cells were obtained from one Saimiri sciureus (PA51) and cultured
for 3, 6, 12, 24, 48, and 72 hrs in the absence or presence of PMA/ionomycin. The relative expression was considered as the expression of the
corresponding genes in PBMC or splenocyte cultured in absence of PMA and ionomycin.
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nex, ELISA, ELISPOT, ICS, and real-time PCR assays.
The use of five assays specific for humans (CBA,
Luminex, ELISA, ELISPOT and ICS) facilitated the de-
tection of a limited number of cytokines in NHP, in-
cluding IL-2 in humans and NHP with CBA and
Luminex, IL-4 and IFN-γ with ELISPOT and ELISA
and IFN-γ with ICS. These findings may reflect the re-
duced specificity of human monoclonal antibodies to
Saimiri cytokines. A previous study reported difficulty
in detecting TNF from Old World monkeys using com-
mercial enzyme-linked immunoassay kits designed for
the detection and quantification of human TNF [49]. It
was suggested that the 62- to 72-amino acid region of
TNF might contribute to the specificity of monoclonal
antibodies to this cytokine in humans. Furthermore,
this region in the Saimiri sequence is highly divergent,
with six substitutions and the addition of a glutamine
residue at position 62. These alterations may reduce
the cross-reactivity of monoclonal antibodies with Sai-
miri TNF, a fact that should be considered when using
this antibody for the detection and quantification of
TNF from Saimiri sciureus. The effect of small se-
quence differences in the recognition of orthologous
molecules in different species has also been illustrated
in studies showing that the injection of recombinanthuman cytokines in NHP induced potent neutralizing
antibody responses against these cytokines, even con-
sidering the high homologies (>95%) in the peptide and
nucleotide sequences [28]. Differences in the sequences
and conformations might also explain the results previ-
ously obtained by using a panel of 67 monoclonal anti-
bodies from different manufacturers to define the
reactivity of these molecules against CD markers in
Saimiri mononuclear cells [50]. In some cases, ad-
equate reactivity was observed, with variation in the
intensity of staining depending on the clone and manu-
facturer used, although in many cases no reactivity was
detected. Similarly, one study tested 204 antibodies
against various human CD markers, and only 28% of
these molecules reacted with Aotus splenocytes [51];
approximately 40% of the reacting antibodies also rec-
ognized rhesus and cynomolgus cells. The use of NHP
CBA only facilitated the detection of IL-2, reflecting
the broader specificity of antibodies to human cyto-
kines that also cross-react with rhesus, cynomolgus,
baboon and pig-tailed macaque cytokines. These find-
ings highlight the need for the development of im-
munological tools for cytokine detection in S. sciureus.
Gene expression of cytokines in cell cultures from S.
sciureus was evaluated. First, gene expression analysis
was performed using TaqMan® Gene Expression Array
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the detection of 28 human cytokine transcripts. These
results revealed the detection of 12 (IL-1A, IL-2, IL-4,
IL-5, IL-6, IL-10, IL-12B, IL-17, IFN-β, IFN-γ, LTA, and
TNF) of the 28 cytokines and two housekeeping genes.
However, only seven (IL-1A, IL-2, IL-10, IL-12, IL-17,
IFN-β, and TNF) of these cytokines presented a relative
quantification of at least 70% of the gene expression ob-
served in human cells after mitogenic stimulation. The
failure in the amplification of some cytokines may reflect
the partial similarity between sequences in Saimiri and
the corresponding genes in humans [33]. However, when
comparing the mRNA sequences for the cytokines from S.
sciureus obtained from GenBank with human sequences
using the Basic Local Alignment Search Tool (BLAST),
similar degrees of identity between the amplified and non-
amplified cytokines were observed. For example, the degree
of identity for the genes encoding IL-4 (not amplified) and
TNF (amplified) between humans and S. sciureus was 92%.
Thus, the failure in the amplification of some cytokines
most likely reflects small changes in the existing sequences
between the human gene and the corresponding Saimiri
gene, leading to an imperfect annealing of the primer to the
DNA template.
Among the 12 cytokines initially amplified, five (IL-4,
IL-5, IL-6, LTA, and IFN-γ) showed relative expression
levels below the threshold of 70% of the gene expression
observed in human cells. However, when primers and
probes specific for S. sciureus were designed from the
published sequences in GenBank, it was possible to de-
tect these cytokine transcripts in mononuclear cells from
S. sciureus, highlighting the need for the design and use
of specific reagents for use with these models, as small
differences in sequences can result in difficulties or even
preclude proper annealing.
Moreover, PBMC and splenocytes from one S. sciureus
sample were cultured in the presence or absence of
stimuli classically used to stimulate cells in vitro (PMA/
ionomycin) since Ag specific stimuli would not be broad
enough to a detectable activation of cells for 3, 6, 12, 24,
48, and 72 hrs to evaluate the kinetics of IL-1A, IL-2,
IL-4, IL-5, IL-6, IL-10, IL-12B, IL-17A, TNF, IFN-β,
LTA, and IFN-γ expression. The results demonstrated
the gene expression of these cytokines in both PBMC
and splenocytes cultures. Furthermore, the results showed
that the cytokine transcripts were detected after 6 and
12 hrs of culture, showing the detection of IL-2, IL-6, IL-
10, IL-12, IFN-γ, TNF, and LTA transcripts after 6 hrs of
Saimiri PBMC culture in the presence of PMA/ionomy-
cin. These results are in agreement with a previous report
showing similar patterns of gene expression of these
cytokines upon PMA/ionomycin stimulation of Saimiri
splenocytes using Saimiri-specific primers in SYBR-green-
based real time PCR assays [52].Unfortunately, cytokines IL-1B, IL-3, IL-8, IL-9, IL-12A,
IL-13, IL-15, IL-16, IL-18, IFN-α1, IFN-α2, IFN-α6, IFN-α7,
IFN-α8, IFN-α16, or IFN-α17 were not successfully amplified.
Amplification of these genes therefore requires additional ef-
fort to define primers and probes, as the sequences for these
genes in S. sciureus have not been published.
Conclusions
In the present study, a variety of techniques to extend
the range of reagents available for NHP research, with
the aim of facilitating a more thorough evaluation of the
immune response in the Saimiri sciureus experimental
model of human Plasmodium infection was assessed.
The data presented herein validate the approach used
for the extension of the available reagent range, facilitat-
ing a more thorough evaluation of the immune response
in this model.
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